The Medical Research Council has announced a £50 million investment in a new centre aimed at improving treatments for mitochondrial diseases, a group of genetic disorders that affect around one in 5,000 people and currently have no cure. The new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics will bring together experts from several disciplines to study how mutations in mitochondrial DNA cause disease and how that knowledge can be translated into therapies.
The announcement marks a major step in research into a set of conditions that can lead to severe disability, progressive decline and premature death. Beyond inherited mitochondrial disorders, mutations in mitochondrial DNA are also increasingly linked to neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration, according to the MRC.
UK-led research aims to turn basic science into treatment
The centre will be led by the University of Cambridge and will partner with the University of Birmingham, The University of Manchester, Heidelberg University, the University of Queensland and the Imagine Institute in Paris. It will also work with charities including the Lily Foundation and industry partners worldwide. The MRC said the collaboration is designed to build a long-term UK research platform with the scale, expertise and infrastructure needed to position the country as a global leader in mitochondrial genome therapeutics.
Project lead Professor Michal Minczuk said the programme will provide new approaches to understanding and treating diseases caused by mutations in the mitochondrial genome. The goal, he said, is to create the scientific foundations for entirely new therapeutic strategies and offer renewed hope to patients and families affected by mitochondrial disease.
Building on earlier milestones in mitochondrial science
Dr Ceri Williams, Executive Director of Challenge Led Themes at the MRC, said the UK has already played a leading role in mitochondrial science, including the development of mitochondrial replacement therapy, which prevents the inheritance of mtDNA mutations. She said the new centre builds on that foundation by bringing together expertise from around the world and across sectors to better understand the root causes of mtDNA mutations and improve prevention, detection and treatment.
Liz Curtis, chief executive officer and founder of the Lily Foundation, said the patient charity is proud to be a named partner in the initiative. She said the project’s collaborative structure and focus on patient perspectives from the outset make it the kind of strategic research effort needed to drive progress towards future treatments.
The investment adds momentum to UK research into rare and complex genetic disease at a time when clinicians and families continue to face major unmet medical needs. By combining laboratory science, clinical expertise and patient input, the new centre is expected to shape the next phase of research into mitochondrial disease and related conditions.
Photo source: AI-generated or edited image
